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Abstract 
Introduction: Placenta-derived exosomes may represent an additional pathway by 
which the placenta communicates with the maternal system to induce maternal 
vascular adaptations to pregnancy and it may be affected during Fetal growth 
restriction (FGR). The objective of this study was to quantify the concentration of 
total and placenta-derived exosomes in maternal and fetal circulation in small fetuses 
classified as FGR or small for gestational age (SGA). 
Methods: Prospective cohort study in singleton term gestations including 10 
normally grown fetuses and 20 small fetuses, sub-classified into SGA and FGR 
accordingly to birth weight (BW) percentile and fetoplacental Doppler. Exosomes 
were isolated from maternal and fetal plasma and characterized by morphology, 
enrichment of exosomal proteins, and size distribution by electron microscopy, 
western blot, and nanoparticle tracking analysis, respectively. Total and specific 
placenta-derived exosomes were determined using quantum dots coupled with 
CD63+ve and placental-type alkaline phosphatase (PLAP)+ve antibodies, respectively. 
Results: Maternal concentrations of CD63+ve and PLAP+ve exosomes were similar 
between the groups (all p>0.05). However, there was a significant positive correlation 
between the ratio of placental-derived to total exosomes (PLAP+ve ratio) and BW 
percentile, [rho=0.77 (95% CI: 0.57 to 0.89); p=0.0001]. The contribution of placental 
exosomes to the total exosome concentration in maternal and fetal circulation showed 
a significant decrease among cases, with lower PLAP+ve ratios in FGR compared to 
controls and SGA cases.  
Discussion: Quantification of placental exosomes in maternal plasma reflects fetal 
growth and it may be a useful indicator of placental function.  
 
Key words: Extracellular vesicles, intrauterine growth, non-invasive diagnosis, 
placenta, and pregnancy. 
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Introduction 1 
 2 
Fetal growth restriction (FGR) affects 7-10% of all pregnancies and is defined as the failure to 3 
achieve the genetic growth potential [1,2]. Growth restricted fetuses have a 5 to 10-fold risk 4 
of dying in-utero, and a higher risk of perinatal morbidity and mortality [3]. Prenatal 5 
identification of FGR has been shown to significantly reduce perinatal morbidity and 6 
mortality, by 4 to 5-fold [4]. However, accurate identification of sub-optimal fetal growth in-7 
utero remains to be an unsolved problem [5]. Detection of fetal smallness has proven elusive, 8 
with high-quality ultrasound programs detecting not more than 50% of the cases [6]. Current 9 
understanding of the clinical classification of small fetuses encompasses two different forms: 10 
Fetal growth restriction (FGR) and small for gestational age (SGA) fetuses. Recently, there 11 
has been great interest on the field of extracellular vesicles (EVs). EVs can be classified 12 
according to their size and origin as exosomes and microvesicles [7]. Exosomes are 13 
membrane-bound vesicles with a diameter of ~40-120 nm, enriched with endosomal protein 14 
markers (e.g. TSG101 and CD63) [8], that are actively released from all types of cells into the 15 
extracellular environment upon exocytic fusion of multivesicular endosomes with the cell 16 
membrane. Several studies have reported that exosomes are key players for intercellular 17 
communication and carry diverse molecular components such as proteins [9], lipids [10], 18 
miRNA [11], and membrane receptors. Exosomes are transferred to adjacent and/or distal 19 
cells in the extracellular space under physiological and pathological conditions [12], making 20 
them a novel mechanism of paracrine and autocrine regulation, which have even been used as 21 
natural nanocarriers to deliver therapeutic agents to injured cells [13]. 22 
The discovery of circulating fetal genetic material in maternal plasma has accelerated the 23 
generation of new potential tools for non-invasive prenatal diagnosis. Placenta-derived 24 
exosomes are unique compared to other exosomes due to the presence of specific proteins like 25 
the placental-type alkaline phosphatase (PLAP) [14–17] and HLA-G [18], as well as miRNAs 26 
such as those within the chromosome 19 miRNA cluster [19–21]. It has been shown that 27 
exosomes are released from the placenta into the maternal circulation from as early as ~7 28 
weeks of gestation, and the concentration of placenta-derived exosomes increases throughout 29 
gestation [22]. This release is tightly regulated by a number of factors, such as oxygen tension 30 
and glucose concentration [9,23,24]. Interestingly, exosome release correlates with placental 31 
mass and perfusion in normal pregnancy [16]. Placenta-derived exosomes may represent an 32 
additional pathway by which the placenta communicates with the maternal system to induce 33 
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maternal vascular adaptations to pregnancy and development of maternal-fetal vascular 34 
exchange [25,26]. However, the precise function and significance of placental exosomes 35 
during pregnancy remain to be elucidated. The aim of this study was to quantify the 36 
concentration of total and placenta-derived exosomes in maternal and fetal circulation in 37 
small fetuses classified as FGR or SGA. In this study we demonstrated the presence of 38 
placental exosomes in maternal and fetal circulation using western blot, then we quantified 39 
the number of circulating placental and non-placental exosomes using quantum dots coupled 40 
with CD63+ve or PLAP+ve, and a commercial ELISA for PLAP  in maternal and fetal 41 
circulation in pregnancies complicated by sub-optimal fetal growth. The specificity of the 42 
methods used in this study were validated using placental tissue (positive control for PLAP) 43 
and exosomes isolated from non-pregnant women (negative control for PLAP).  44 
 45 
Methods 46 
Study groups and data collection 47 
This was a prospective cohort study, including singleton gestations that were enrolled at third 48 
trimester between December 2014 and June 2016 and delivered at Department of Maternal-49 
Fetal Medicine in BCNatal, Barcelona, Spain. Plasma samples were obtained in accordance 50 
with the declaration of Helsinki, the institutional ethics committee approved the study 51 
protocol (IRB 2014/7154) and all patients provided written informed consent. All pregnant 52 
women included in this study were normotensive and without intrauterine infection or any 53 
other medical or obstetric complications who delivered at term (> 37 weeks). Pregnancies 54 
with a fetal congenital or chromosomal anomaly were ineligible to participate. Study groups 55 
included: (1) pregnancies with a normally grown fetuses who delivered appropriately for 56 
gestational age neonates (n=10) and (2) pregnancies complicated with sub-optimal fetal 57 
growth who delivered neonates with a BW <10th centile by local reference customized 58 
standards (n=20) [27]. Additionally, small fetuses were sub-classified according to clinical 59 
severity into small for gestational age (SGA) if the BW percentile was between the 3rd and the 60 
9th centile and the fetoplacental Doppler was normal (n=10) and as FGR to those fetuses with 61 
a BW of less than the 3rd centile and/or either abnormal cerebroplacental ratio (CPR) (< 5th 62 
centile) and/or the uterine artery Doppler pulsatility index (UtA-PI) was > the 95th centile 63 
(n=10) [2]. See Supplementary Methods. 64 
 65 
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Isolation of exosomes from maternal and fetal samples 66 
Exosomes were isolated from plasma (1 ml) as previously described [17]. In brief, plasma 67 
was centrifuged at 800 x g for 10 min, 2,000 x g for 30 min at 4 0C, 2,000 x g, 12,000 x g for 68 
45 min at 4 0C, and 100,000 x g for 2 h (Sorvall, T-8100, fixed angle ultracentrifuge rotor). 69 
The pellet (500 µl) was layered on the top of a discontinuous iodixanol gradient containing 70 
40% (w/v), 20% (w/v), 10% (w/v) and 5% (w/v) iodixanol (solutions were made by diluting a 71 
stock solution of OptiPrep™ (60% (w/v) aqueous iodixanol from Sigma-Aldrich) and 72 
centrifuged at 100,000 g for 20 h. Fractions were collected manually from top to bottom (with 73 
increasing density), diluted with PBS and centrifuged at 100,000 g for 2h at 4o C. Finally, the 74 
pellet containing the enriched exosome population was resuspended in 50 µl PBS. Exosomes 75 
were characterized by size distribution, abundance of proteins associated with exosomes (i.e. 76 
CD63, sc15363; Flotillin-1, sc25506; and TSG101, EPR7130), placenta-derived exosomes 77 
(PLAP, ab96588) and a negative control for Grp94 (20292T)), and morphology accordantly to 78 
the recommendation of the international society of extracellular vesicles using Nanoparticle 79 
Tracking Analysis (NTA), Western blot analysis and electron microscopy, respectively. See 80 
Supplementary Methods.  81 
 82 
Quantification of total exosomes and placenta-derived exosomes 83 
Using immunofluorescent NTA in fluorescence mode, the concentration of total and placenta-84 
derived exosomes in maternal plasma was quantified using quantum dots coupled with CD63 85 
or PLAP as we previously described [17]. PLAP is a syncytiotrophoblast-specific marker; 86 
therefore, exosomes derived from placental origin are positive for PLAP [16]. Qdots (Qdot® 87 
nanocrystals or R-PE) were conjugated to anti-CD63, anti-PLAP (MA1-20245, clone H17E2, 88 
ThermoFisher) or IgG1 isotype control antibody (IgG1 sc-34665, Santa Cruz Biotechnology) 89 
with a SiteClick Qdot 605 Antibody Conjugation Kit (Life Technologies) according to the 90 
manufacturer's instructions as previously described [17]. Five videos x 60 s each were 91 
captured for each sample and analyzed. The quantification of PLAP in the exosomal fraction 92 
indicates the relative concentration of placental-derived exosomes (PLAP+ exosomes) in 93 
maternal and fetal circulation. Finally, the concentrations of PLAP-associated exosomes were 94 
quantified using a commercial Placental Alkaline Phosphatase (PLAP) ELISA kits 95 
(MyBiosource; Cat# MBS289869) as we previously described [20]. See Supplementary 96 
Methods. 97 
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 98 
Statistical analysis 99 
See Supplementary Methods. 100 
 101 
Results 102 
Clinical characteristics of the study population 103 
Table 1 shows the clinical characteristics, perinatal outcomes and morphometric 104 
characteristics of the placenta in normal patients who delivered at term as well as those who 105 
had small for gestational age and growth-restricted fetuses. There were no significant 106 
differences in respect to maternal age, BMI, smoking, ethnicity, fetal gender or nulliparity. 107 
Although, smoking during pregnancy was only identified in FGR group. At ultrasound 108 
evaluation, as expected, fetuses with sub-optimal fetal growth had significantly lower 109 
estimated fetal weight percentile and also worst values in the fetoplacental Doppler 110 
parameters (Table 1). Although there was no significant difference in the gestational age at 111 
delivery between cases and controls, birth weight centile, placental weight and breadth was 112 
significantly lower in cases with sub-optimal fetal growth. The rate of obstetric interventions 113 
such as induction of labor and cesarean section were significantly higher in the group of 114 
patients with FGR compare to controls (Table 1). 115 
 116 
Characterization of total and placental-derived exosomes 117 
Exosomes were isolated from maternal and fetal plasma by differential and buoyant density 118 
centrifugation (Supplemental material Figure S1). The distribution of particles and size 119 
distribution of total (CD63+) and placenta-derived exosomes (PLAP+ve) across the fractions in 120 
maternal and fetal plasma is presented in Supplemental material Figure S2).   In maternal 121 
plasma, the size distribution was 87 ± 23 nm, 82 ± 18 nm and 108 ± 37 nm for controls, SGA, 122 
and FGR groups, respectively (Figure 1C). In fetal plasma, the size distribution was 90 ± 17 123 
nm, 85 ± 17 nm and 81 ± 15 nm for controls, SGA and FGR groups, respectively (Figure 1D). 124 
No significant differences were observed in the size distribution of exosomes between groups 125 
and/or maternal and fetal plasma. Exosome enriched fractions from maternal and fetal plasma 126 
contained vesicles of around 100 nm diameter identified by electron microscopy (Figure 1C 127 
and 1D). Exosomes were positive for CD63, Flotillin-1, and TSG101 (Figure 1A), which are 128 
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proteins associated with exosomes. Interestingly, the enrichment of exosomes was negative 129 
for Grp94 (Figure 1A), which is an endoplasmic reticulum marker and demonstrated the 130 
purity of the exosome isolation. The abundance of these proteins was not significantly 131 
affected between controls, SGA and FGR groups. Therefore, these results confirmed the 132 
reproducibility of our method to enrich a specific type of EVs defined by enrichment of 133 
proteins associated with exosomes (i.e. CD63, Flotillin-1, and TSG101) and lack of Grp94 134 
(negative control); size distribution of ~100 nm (within of the size of exosomes) and spherical 135 
morphology. 136 
The presence of exosomes from placental origin in maternal plasma was confirmed by the 137 
presence of PLAP by Western blot (Figure 1B e). Interestingly, exosomes isolated from fetal 138 
plasma were positive for PLAP (Figure 1B e). Therefore, our next step was quantified the 139 
number of total exosomes and placenta-derived exosomes in maternal and fetal circulation. 140 
We did not find PLAP protein in exosomes isolated from non-pregnant women (Supplemental 141 
material Figure S3). 142 
 143 
Exosomal profile in maternal blood  144 
The total number of exosomes (Qdot-CD63+ve) and placenta-derived exosomes (Qdot-145 
PLAP+ve) in the maternal circulation was not affected by maternal age, parity or pre-146 
gestational maternal BMI (Supplemental material Table S2). There were no correlations 147 
between maternal plasma exosomes, birth weight or placental characteristics. The 148 
concentration of total exosomes (CD63+ve), Placenta-derived exosomes (CD63+ve and 149 
PLAP+ve), non-placenta-derived exosomes (CD63+ve and PLAP-ve), and the contribution of 150 
placental exosomes to the total exosomal concentration (CD63+ve and PLAP+ve / CD63+ve and 151 
PLAP-ve x 100) in cases and controls are presented in Figure 2. The total number of 152 
circulating exosomes was significantly differences (ANOVA p<0.05) across the groups 153 
studied (Figure 2A). There were no significant differences in the maternal plasma 154 
concentration of placenta-derived exosomes between cases (SGA and FGR) and controls 155 
(Figure 2B). However, the contribution of non-placental and placental exosomes was 156 
significantly different (ANOVA ***p<0.0001) (Figure 2 C and D). Interestingly, the levels of 157 
exosomes from non-placental origin were significantly lower in SGA compared to FGR and 158 
controls (Bonferroni’s multiple comparisons test **p<0.001). Similarly, the levels of 159 
placenta-derived exosomes were significantly lower in SGA and FGR compared to controls 160 
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(Bonferroni’s multiple comparisons test **p<0.001). Interestingly, when cases with sub-161 
optimal fetal growth were sub-classified according to the severity of the cases in small for 162 
gestational age (normal feto-placental Doppler and birth weight percentile between 9 and 3) 163 
and fetal growth restriction (Abnormal fetoplacental Doppler and/or birth weight percentile 164 
below the third percentile), the contribution of placental exosomes to the total exosome 165 
showed a significant decrease among cases, with lower PLAP+ve ratios in FGR compared to 166 
controls and SGA cases (Figure 2). Maternal PLAP+ve ratio has a significant positive 167 
correlation with birth weight percentile [Spearman correlation=0.77 (95% CI: 0.57 to 0.89); 168 
p=0.0001], but no significant correlation with placental characteristics or fetoplacental 169 
Doppler (Supplemental material Table S1). The individual values of total and placenta-170 
derived exosomes present in maternal circulation are presented in Supplemental material table 171 
S2. The presence of PLAP in exosomes isolated from maternal circulation was confirmed 172 
using a commercial ELISA kit (Supplemental material Figure S4A). We did not find a 173 
significant difference in the PLAP-associated exosomes across the studied groups.  174 
 175 
Exosomal profile in fetal blood  176 
The total number of exosomes (Qdot-CD63+ve) and placenta-derived exosomes (Qdot-177 
PLAP+ve) in the fetal circulation was not affected by parity or fetal gender. There were no 178 
significant differences in the total and placenta-derived exosomes among the study groups 179 
(Figure 3A and B). Interestingly, the contribution of non-placental and placental-derived 180 
exosomes to the total circulating exosomes significantly different among the groups, with a 181 
significant decrease among cases (Figures 3 C and D). Similarly to the profile in maternal 182 
plasma, we identified significant changes in the contribution of non-placental and placental 183 
exosomes to the total concentration of circulating exosomes between the study groups 184 
(ANOVA, p<0.0001). Post hoc multiple comparison test (Bonferroni) showed statistical 185 
difference (**p<0.005) between SGA or FGR compared to controls (Figure 3 C and D). The 186 
contribution of non-placental to the total exosomes was higher in SGA and FGR compared to 187 
controls. On the other hand, the contribution of placental-derived to the total exosomes was 188 
lower in SGA and FGR compared to controls. No significantly different between SGA and 189 
FGR for non-placenta and placenta-derived exosomes were identified. No significant effects 190 
of fetal gender, maternal characteristics or fetoplacental Doppler on CD63+ve or PLAP+ve 191 
exosomes in fetal blood were identified (Supplemental material Table S1). However, when 192 
the contribution of placenta-derived exosomes was determined in fetal blood plasma, strong 193 
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and significant positives correlations with birth weight percentile, placental weight and 194 
breadth were obtained (r=0.91; 0,71 and 0,80, respectively; all p<0.05) (Supplemental 195 
material Table S1). The individual values of total and placenta-derived exosomes present in 196 
fetal circulation are presented in Supplemental material table S3. The presence of PLAP in 197 
exosomes isolated from fetal circulation was confirmed using a commercial ELISA kit 198 
(Supplemental material Figure S4B). We did not find a significant difference in the PLAP-199 
associated exosomes across the studied groups. Placental tissue and exosomes isolated from 200 
non-pregnant women were used as positive and negative control, respectively (Supplemental 201 
material Figure S4C). 202 
 203 
Comparison analysis on the circulating exosomes between maternal and fetal circulation 204 
To compare the number of total, placenta-derived and contribution of non-placental and 205 
placental exosomes between maternal and fetal circulation, a two-way ANOVA with variance 206 
partitioned between pregnancy condition (i.e. controls, SGA and FGR) and circulation (i.e. 207 
maternal or fetal) was used (Figure 4). The concentration of exosomes including total, 208 
placenta-derived and the proportion of non-placenta and placental origin compared to the total 209 
exosomes was significantly different between maternal and fetal circulation. Post hoc multiple 210 
comparison test (Bonferroni) showed statistical difference (**p<0.005) in the SGA group in 211 
both total and placenta derived exosomes (Figure 4A and B). Interestingly, significantly 212 
difference between maternal and fetal circulation on the contribution of non-placental (Figure 213 
4C) and placenta-derived (Figure 4D) exosomes to the total exosomes were identified for 214 
each group (i.e. controls, SGA and FGR). 215 
Finally, correlation analysis on the total, placenta-derived, and proportion of non-placenta and 216 
placental origin compared to the total circulating exosomes between fetal and maternal 217 
plasma was performed (Supplemental material Figure S5). Interestingly, a significant positive 218 
correlation between the contribution of placenta-derived exosomes to the total exosomes 219 
present between fetal and maternal circulation was identified (Figure 5C). 220 
 221 
Discussion 222 
The principal findings of this study are: 1) The contribution of placental exosomes (CD63+ve 223 
and PLAP+ve) to the total circulating exosomes (CD63+ve) is an indicator of fetal growth 224 
(significant and positive correlation with neonatal and placental weight); 2) The proportion of 225 
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circulating placental exosomes compared to the total exosomes was significantly reduced in 226 
small fetuses as compared to controls, and displays a clear trend according to the severity of 227 
the disease (more reduced in cases with abnormal Doppler or severe growth restriction) and 3) 228 
A positive correlation between maternal and fetal circulation on the contribution of placental 229 
exosomes to the total circulation exosomes was identified, suggesting a potential mechanism 230 
of regulation to maintain the proportion of exosomes between these circulation.  231 
In this study, we isolate exosomes using a density gradient and every fraction was analysed  232 
by nanoparticle tracking analysis in fluorescence mode using quantum dots coupled with 233 
CD63 or PLAP and classified by size in <35 nm, 35-150 nm, and >150 nm. As we showed in 234 
the supplemental figure S2, between fractions 4 to 8 (i.e. density of 1.12 to 1.18g/ml) 235 
contained a greater number of vesicles with a majority of 50–150 nm in diameter, compared 236 
to the other fractions. Therefore, floatation into iodixanol gradients allows the enrichment of 237 
exosomes with a high yield of vesicles CD63+ve. We would like to highlight that this is the 238 
first study reporting the individual number of vesicles CD63+ve and PLAP+ve in every fraction 239 
of an iodixanol gradient. 240 
Using NTA in fluorescence mode, we establish the presence of exosomes (total and placental) 241 
in maternal and fetal circulation, and only individual vesicles were quantified. In addition, the 242 
presence of PLAP in exosomes isolated from maternal and fetal plasma was confirmed using 243 
a commercial ELISA kit. In order to quantify the number of placental-derived exosomes, we 244 
used placental-type alkaline phosphatase (PLAP+ve), a plasma membrane enzyme isoform 245 
specifically produced by the syncytiotrophoblast [18]. PLAP+ve exosomes are specific for 246 
pregnancy and are not found in the circulation of non-pregnant women [15,16]. Herein, we 247 
are reporting that the contribution of placental exosomes (expressed as percentage of 248 
exosomes positive for PLAP+ve compared to total exosomes CD63+ve) in the maternal 249 
circulation was ~14% lower in SGA and until ~23% lower in patients with FGR and it may be 250 
used as a marker for placental insufficiency and fetal growth. However, a larger trial is 251 
required to further validate utility of this approach for population screening. 252 
Within the maternal circulation, the exosome population is secreted from multiple cell types, 253 
such as erythrocytes [28], endothelial cells [29], lymphocytes and dendritic cells, in addition 254 
to the placenta during gestation. During pregnancy, exosomes are involved in cell-to-cell 255 
communication between the placenta and maternal immune system [8]. Placenta derived 256 
exosomes suppress maternal T-cell signaling, which is thought to promote maternal 257 
immunotolerance towards the fetal allograft [15]. This local immune privilege at the feto-258 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9  
 
 
maternal interface has been attributed to the expression of placental exosome-associated 259 
functional Fas ligand (FasL), programmed death ligand 1 (PD-L1) and TNF-related apoptosis 260 
inducing ligand (TRAIL), which all induce maternal T-cell anergy and death [15, 30]. The 261 
expression of NKG2D receptor ligands, UL-16 binding proteins (ULBP) and MHC class I 262 
chain-related (MIC) proteins on placental exosomes have been shown to down regulate NK 263 
cell activity and suppress maternal cytotoxic activity [31], thereby promoting fetal allograft 264 
survival. In normal pregnancies, placental exosomes have been reported to interact with and 265 
modulate the function of maternal endothelium to promote trophoblast migration, 266 
angiogenesis and spiral artery remodeling [32]. However, under pro-inflammatory (i.e. 267 
hypoxia and obesity) or pathological conditions such as gestational diabetes, the number of 268 
circulating exosomes is higher and promoting the release of pro-inflammatory cytokines from 269 
endothelial cells [21,33]. This suggests that the content and effects of exosomes depends on 270 
the pathological and physiological status of the pregnant woman.  271 
This is the first study, reporting the presence of exosomes positive for PLAP in fetal 272 
circulation in human subjects, and showing its relation with fetal growth. The presence of 273 
PLAP in exosomes isolated from fetal circulation was evaluated using different methods, 274 
including western blot, nanoparticle tracking analysis, and ELISA. These methods are 275 
antibodies based which might be one of the limitations of this study. However, we used three 276 
different antibodies for PLAP. The antibody PLAP, ab96588 was used for Western blot and 277 
the antibody anti-PLAP MA1-20245, clone H17E2, ThermoFisher was used for the 278 
quantification of placental exosomes by fluorescence nanoparticle tracking analysis. The 279 
antibody from Abcam has been validated for western for the company and the antibody anti-280 
PLAP MA1-20245, clone H17E2, ThermoFisher has been validated for flow cytometer which 281 
uses the same principle of nanoparticle tracking analysis. Moreover, the clone H17E2 has 282 
been previously showed to be non-cross reactive to both human liver and intestinal alkaline 283 
phosphatases [34]. We used a commercial ELISA kit for PLAP to validate the presence of 284 
exosomes positive for PLAP in maternal and fetal circulation. For each analysis, we used 285 
exosomes isolated from non-pregnant women as negative control for PLAP as we previously 286 
described [17]. 287 
PLAP exosomes in umbilical cord blood and serum in pregnant sheep has been previously 288 
reported, and interestingly, exosome-associated miRNAs identified in the maternal and fetal 289 
circulation were differently expressed [35]. Several studies have detected exosomes isolated 290 
from mesenchymal stem cells obtained from fetal blood, and have also discussed their role in 291 
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different clinical implications including decreased liver fibrosis [36], inflammation [37] and 292 
response to chemotherapy [38]. Interestingly, it has been recently reported that proteomic 293 
analysis of total exosomes isolated from umbilical cord blood of neonates that were born from 294 
mothers with preeclampsia was significantly different compared to those born from normal 295 
healthy pregnancies [39]. Placenta is a specialized barrier between the mother and fetus, 296 
which is the major route for transfer of nutrients, gases and ions to the fetus and has 297 
predominant role in fetal growth and development. Even maternal cells can cross placenta and 298 
reach fetal circulation and can lodge in fetal organs, which is called microchimerism [40]. The 299 
transmigration of the maternal cells to the fetal side is by interaction of Vascular endothelial 300 
growth factor (VEGF A) and Vascular endothelial growth factor receptor 1 (VEGFR-1), with 301 
the help of cell surface integrins [41]. VEGF A has been described as the vascular 302 
permeability factor. Vessel fenestrations induced by VEGF A in the form of caveolae or 303 
assembly of caveolae to form trans-endothelial pores help in the passage of small molecules. 304 
However, larger proteins and cells depend on VEGF-cadherin based loosening of tight 305 
junctions and passage between endothelial cells [42]. Nevertheless, exosomes originating 306 
from the endosomal pathway and released into the extracellular space can enter the systemic 307 
circulation and taken up by different cells [43,44]. Thus, exosomes could be permeating 308 
through the endothelial barrier by any of the above means to enter the systemic circulation. 309 
Even the blood-brain barrier comprising of specialized endothelial cells with multimolecular 310 
complex tight junctions is permeable to exosomes and can be specifically used to deliver 311 
cargo to the neuronal cells [45,46]. 312 
Although the dichotomous view of suboptimal fetal growth as a SGA or FGR is overly naive, 313 
the contributions of placental insufficiency differ between both conditions, ultimately 314 
resulting in a diverse spectrum of clinical presentations. The release of exosomes to the 315 
maternal circulation is an active process, with purpose and regulated by tissue physiology and 316 
cellular function [30]. In contrast, the release of syncytiotrophoblast apoptotic debris appears 317 
to be a stimulus for a systemic inflammatory response [47]. Thus, a reduced secretion of 318 
placental derived exosomes may reduce maternal-fetal tolerance, predisposing to placental 319 
damage and apoptosis, which in turns lead to systemic maternal inflammation. 320 
Herein, we quantified the number of placental exosomes present in maternal and fetal 321 
circulation (i.e. individual exosomes positive PLAP were tracked) and established the 322 
contribution of placental exosomes to total exosomes in maternal and fetal circulation in 323 
pregnancies with different degrees of fetal growth. All subgroups of small fetuses were 324 
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associated with significant alteration in the placental-derived exosomes profile, but there was 325 
a gradation according to the severity of the disease. The presence of significant differences in 326 
mother and SGA fetuses supports the view that at least a large proportion of these fetuses are 327 
not “constitutionally” small, indicating some degree of placental dysfunction and challenging 328 
the concept of constitutionally small. In order to determine the role of exosomes originating 329 
from different sources present in maternal and fetal circulation, further studies are required. 330 
As we discussed, the presence of exosomal PLAP in fetal circulation was determined using 331 
antibodies based methods. Therefore, we suggest that additional experiments using different 332 
methodologies might be necessary to elucidate the mechanisms of tracking of exosomes from 333 
maternal to fetal circulation. This study provides proof-of-concept that quantification of 334 
placenta-derived exosomes may facilitate the early identification of suboptimal fetal growth. 335 
We believe that the analysis of placenta-derived exosomes in maternal blood may represent in 336 
the future a clinically useful, non-invasive test for placental function and/or dysfunction.  337 
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Tables and Figure legends 501 
 502 
Table 1. Baseline, pregnancy and perinatal characteristics of the study population subdivided into 503 
uncomplicated pregnancies with normal birth weight (controls) and small fetuses.  504 
 505 
 
Uncomplicated 
pregnancies 
(N=10) 
Small for 
Gestational Age 
(N=10) 
Fetal Growth 
Restriction 
(N=10) 
 
Characteristics Median (IQR)  
or n (%) 
Median (IQR)  
or n (%) 
Median (IQR)  
or n (%) p value 
Maternal baseline characteristics     
  Age (years) 33 (31 – 34) 31.5 (25 – 35) 33 (26 – 35) 0.91 
  BMI (kg/m2) 23.7 (21.7 – 24.6) 21.6 (19.9 – 23.1) 21.6 (20.4 – 23.7) 0.67 
  Ethnicity    0.31 
    White 6 (60) 8 (80) 5 (50)  
    Latin 2 (20) 0 4 (40)  
    Others 2 (20) 2 (20) 1 (10)  
  Nulliparous 5 (50) 5 (50) 7 (70) 0.58 
  Smoking during pregnancy  0 0 2 (20) 0.34 
Feto-placental ultrasound 
    
  Gestational age at ultrasound (weeks) 33.3 (33.1 – 35.5) 33.7 (32 – 35.3) 33.4 (32.4 – 37.3) 0.95 
  EFW percentile 53 (39 – 82) 5 (4 – 7) 4 (2 – 9) 0.003 
  Umbilical artery PI 0.67 (0.63 – 0.72) 1.08 (1 – 1.22) 1.05 (0.89 – 1.14) 0.42 
  Middle cerebral artery PI 1.76 (1.2 – 2.32) 1.63 (1.32 – 1.9) 1.45 (1.22 – 1.66) 0.87 
  IP middle cerebral artery <5th centile 0 0 2 (20) 0.14 
  Cerebro-placental ratio 2.67 (1.67 – 3.68) 1.55 (1.9 – 1.99) 1.45 (1.19 – 1.79) 0.33 
  Cerebro-placental ratio <5th centile 0 0 3 (30) 0.39 
  Mean Uterine artery PI 0.79 (0.66 – 0.87) 0.85 (0.73 – 0.97) 0.8 (0.63 – 0.96) 0.79 
  Mean Uterine artery PI >95th centile 0 0 3 (30) 0.49 
Perinatal outcomes 
    
  Gestational age at delivery (weeks) 40.1 (39.2 – 40.6) 39.4 (38.1 – 40) 38.7 (37.6 – 40.1) 0.18 
  Induction of labor 3 (30) 5 (50) 10 (100) 0.004 
  Cesarean section 1 (10) 1 (10) 0 0.58 
  Male fetal gender 4 (40) 3 (30) 3 (30) 0.86 
  Birth weight (grams) 3372 (3080 – 3500) 2765 (2580 – 2850) 2348 (2328 – 2588) 0.0001 
  Birth weight percentile 45 (32 – 52) 6 (5 – 7) 1 (1 – 2) 0.0001 
  Placental weight (grams) 584 (440 – 610) 397 (345 – 428) 392 (365 – 455) 0.06 
  Placental breadth (cms) 17 (15.5 – 18) 12.5 (11.5 – 14.5) 14 (12 – 14.7) 0.1 
  Birth weight/Placental weight 6.15 (5.5 – 7.9) 7 (6.6 – 7.5) 6.1 (5.5 – 6.4) 0.14 
BMI: Body mass index; EFW: Estimated fetal weight and PI: Pulsatility index. 506 
 507 
 508 
 509 
 510 
 511 
 512 
 513 
 514 
 515 
 516 
 517 
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 519 
Figure 1. Characterization of exosome isolated from maternal and fetal circulation. 520 
Exosomes were isolated from maternal plasma and fetal plasma (i.e. cord blood) by 521 
differential and buoyant density centrifugation from controls (appropriate for gestational age), 522 
small for gestational age (SGA) and fetal growth restriction (FGR) pregnancies. (A) 523 
Representative Western blot (Top) and corresponding SDS-gel stained with with SimplyBlue 524 
SafeStain (bottom) for exosome-enriched marker TSG101, flotilin-1, CD63 and negative 525 
marker Grp94. The presence of exosomes from placental origin was evaluated using Western 526 
for PLAP. Exosomes were positive for CD63, Flotilin-1, and TSG101, which are proteins 527 
associated with exosomes and negative for Grp94, which is an endoplasmic reticulum marker 528 
demonstrating the purity of the exosome isolation. (B and C) Representative size distribution 529 
and electron micrograph (insert) of exosomes isolated from maternal and fetal plasma, 530 
respectively. In A, 1: controls, 2: SGA, 3: FGR, and 4: cell lysate. In B and C, scale bar 100 531 
nm. 532 
 533 
Figure 2. Profile of exosomes in maternal plasma. Quantification of total, placenta-derived 534 
exosomes and their contribution to the total circulating exosomes in maternal plasma. Small 535 
fetuses were subdivided in small for gestational age (SGA) and fetal growth restriction 536 
(FGR), according to the severity of the case. (A) Total exosomes (CD63+ve). (B) Placenta-537 
derived exosomes (CD63+ve and PLAP+ve). (C) The contribution of non-placental exosomes to 538 
the total exosomal concentration (%). (D) The contribution of placental exosomes to the total 539 
exosomal concentration (CD63+ve and PLAP+ve / CD63+ve and PLAP-ve x 100) (%) in cases and 540 
controls. In C and D, *** p<0.0001 and **** p<0.00001. 541 
 542 
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Figure 3. Profile of exosomes in fetal plasma. Quantification of total, placenta-derived 543 
exosomes and their contribution to the total circulating exosomes in fetal plasma. Small 544 
fetuses were subdivided in small for gestational age (SGA) and fetal growth restriction 545 
(FGR), according to the severity of the case. (A) Total exosomes (CD63+ve). (B) Placenta-546 
derived exosomes (CD63+ve and PLAP+ve). (C) The contribution of non-placental exosomes to 547 
the total exosomal concentration (%). (D) The contribution of placental exosomes to the total 548 
exosomal concentration (CD63+ve and PLAP+ve / CD63+ve and PLAP-ve x 100) (%) in cases and 549 
controls. In C and D, *** p<0.0001 and **** p<0.00001. 550 
 551 
Figure 4. Comparison of the profile of exosomes between maternal and fetal plasma. The 552 
populations of circulating exosomes present in maternal and fetal circulation was analysed. 553 
(A) Total exosomes CD63+ve (fold changes). (B) Placental exosomes (CD63+ve & PLAP+ve) –554 
(C) Contribution of non-placental exosomes. (D Contribution of placental exosomes to the 555 
total exosomal concentration. Data were normalised to values in maternal circulation 556 
observed in controls and expressed as fold changes. In A, B and C, * p<0.05 and *** 557 
p<0.0001. 558 
 559 
Figure S1. Correlations between maternal and fetal plasma. Spearman correlation 560 
between: A. Total exosomes CD63+ve per ml plasma between maternal and fetal circulation. 561 
B. Placental exosomes PLAP+ve per ml plasma between maternal and fetal circulation. C. The 562 
contribution of placental to total exosomes between maternal and fetal circulation. D. The 563 
contribution of non-placental to total exosomes between maternal and fetal circulation.  564 
 565 
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Supplemental material 566 
Table S1. Spearman correlation coefficient between maternal and fetal blood plasma concentrations of Qdot-CD63+ve and placental alkaline 567 
phosphatase (PLAP+ve) exosomes and clinical parameters. 568 
 569 
 
Maternal Qdot-CD63+ve 
Spearman correlation 
(95% CI); p value 
Maternal Qdot-PLAP+ve 
Spearman correlation 
(95% CI); p value 
Maternal PLAP+ve ratio  
Spearman correlation 
(95% CI); p value 
Fetal Qdot CD63+ve 
Spearman correlation 
(95% CI); p value 
Fetal Qdot PLAP+ve 
Spearman correlation 
(95% CI); p value 
Fetal PLAP+ve ratio 
Spearman correlation 
(95% CI); p value 
Maternal pre-
gestational BMI (kg/m2) 
0.06 (-0.31 to 0.42) 
p=0.75 
0.07 (-0.30 to 0.43) 
p=0.71 
0.1 (-0.27 to 0.45) 
p=0.6 
0.11 (-0.27 to 0.46) 
p=0.57 
0.19 (-0.19 to 0.52) 
p=0.33 
0.42 (0.06 to 0.68) 
p=0.02 
Uterine artery Doppler 
mean PI (z-scores) 
0.04 (-0.35 to 0.41) 
p=0.85 
-0.01 (-0.39 to 0.37) 
p=0.96 
-0.18 (-0.53 to 0.21) 
p=0.36 
-0.26 (-0.58 to 0.14) 
p=0.20 
-0.28 (-0.60 to 0.11) 
p=0.15 
-0.03 (-0.41 to 0.35) 
p=0.88 
Umbilical artery 
Doppler PI (z-scores) 
-0.02 (-0.39 to 0.35) 
p=0.91 
-0.08 (-0.44 to 0.30) 
p=0.69 
-0.24 (-0.56 to 0.15) 
p=0.22 
0.19 (-0.20 to 0.52) 
p=0.34 
0.15 (-0.23 to 0.50) 
p=0.43 
-0.23 (-0.56 to 0.15) 
p=0.23 
Cerebroplacental ratio -0.09 (-0.52 to 0.38) p=0.72 
-0.02 (-0.47 to 0.44) 
p=0.93 
0.21 (-0.27 to 0.60) 
p=0.40 
-0.19 (-0.59 to 0.29) 
p=0.43 
-0.06 (-0.50 to 0.41) 
p=0.82 
0.44 (-0.02 to 0.75) 
p=0.06 
Birth weight percentile -0.09 (-0.44 to 0.28) p=0.62 
0.03 (-0.34 to 0.38) 
p=0.88 
0.77 (0.57 to 0.89) 
p=0.0001 
-0.29 (-0.59 to 0.08) 
p=0.12 
-0.15 (-0.48 to 0.22) 
p=0.43 
0.91 (0.81 to 0.96) 
p=0.0001 
Placental weight (g) -0.49 (-0.82 to 0.09) p=0.09 
-0.39 (-0.77 to 0.20) 
p=0.19 
0.12 (-0.46 to 0.63) 
p=0.69 
0.20 (-0.39 to 0.68) 
p=0.50 
0.32 (-0.28 to 0.74) 
p=0.29 
0.71 (0.27 to 0.91) 
p=0.01 
Placental breadth (cm) -0.73 (-0.92 to -0.27) p=0.01 
-0.67 (-0.90 to -0.15) 
p=0.02 
0.46 (-0.15 to 0.82) 
p=0.13 
0.13 (-0.48 to 0.66) 
p=0.68 
0.33 (-0.30 to 0.76) 
p=0.29 
0.80 (0.41 to 0.94) 
p=0.001 
Birth weight/Placental 
weight 
0.02 (-0.54 to 0.57) 
p=0.94 
0.01 (-0.54 to 0.56) 
p=0.97 
0.49 (-0.09 to 0.82) 
p=0.09 
-0.15 (-0.65 to 0.43) 
p=0.62 
-0.11 (-0.62 to 0.47) 
p=0.72 
0.13 (-0.45 to 0.64) 
p=0.67 
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Highlights 
• The maternal PLAP+ve ratio is a marker of fetal growth and placental function. 
• Maternal PLAP+ve ratio was ~14% lower in SGA and ~23% lower in patients 
with FGR. 
• The fetal blood PLAP+ve ratio has a similar behavior to the maternal PLAP+ve 
ratio. 
 
